Quartalsergebnisse (Earnings) für AbbVie

zacks.com2026-10-06 12:26:15

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.

zacks.com2026-10-06 10:31:03

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

fool.com2026-10-06 09:50:02

Should You Buy AbbVie Stock Before Oct. 30?

AbbVie has generated solid double-digit growth in its most recent quarters. Additional approvals for its top drugs could lead to more growth.

247wallst.com2026-10-06 08:49:38

$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely

When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory, and together they turn a single portfolio into a reliable cash machine.

247wallst.com2026-10-06 08:25:48

AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News

AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.

defenseworld.net2026-10-06 08:12:45

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

AbbVie (NYSE: ABBV - Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus EPS estimate of 3.850. The company issued revenue guidance of -. Wall Street Analyst Weigh In A number of equities research

defenseworld.net2026-10-06 07:26:44

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

AbbVie (NYSE: ABBV - Get Free Report) updated its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.730-3.770 for the period, compared to the consensus estimate of 3.850. The company issued revenue guidance of -. Analysts Set New Price Targets A number of research firms have recently

zacks.com2026-10-05 18:46:01

Why AbbVie (ABBV) Outpaced the Stock Market Today

AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day.

reuters.com2026-10-05 15:38:18

AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of ‌lymphoma reduced the risk of disease progression or death in a late-stage study.

fool.com2026-10-05 15:15:00

Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October

AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.

EPS (USD)

Umsatz (USD)

Revisionen der Gewinnschätzungen